Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease

NCT02390219 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis
Advanced Lung Disease

Interventions

DRUG: Lumacaftor
DRUG: Ivacaftor

Sponsor

Vertex Pharmaceuticals Incorporated